Gardnerella vaginalis DNA (G. vaginalis DNA)

Gardnerella vaginalis DNA is the genetic material of the anaerobic bacterium Gardnerella vaginalis, which is the primary organism associated with bacterial vaginosis (BV) (StatPearls, 2023). While DNA generally serves as the template for replication and transcription, in G. vaginalis, it acts as a direct pharmacological target for nitroimidazole antibiotics like metronidazole and tinidazole (PubMed, PMID: 30251172). These drugs undergo reductive activation within the anaerobic environment of the bacterium, forming reactive radical intermediates that cause covalent binding and strand breakage of the DNA (NCBI, Bookshelf NBK539728). This damage leads to the inhibition of nucleic acid synthesis and bacterial cell death. Additionally, G. vaginalis DNA is a critical biomarker used in clinical diagnostics, where its presence is detected via polymerase chain reaction (PCR) to identify BV in symptomatic patients (CDC, 2021). The structural integrity of this DNA is essential for the survival and virulence of the pathogen within the vaginal microbiome. Targeting the DNA allows for selective toxicity against anaerobic species that possess the necessary reductive pathways. However, the emergence of resistant strains and the formation of biofilms can protect the DNA from drug-induced damage, presenting a significant therapeutic challenge.

Other names

Gardnerella DNAG. vaginalis genomic DNAGardnerella vaginalis chromosome

Nitroimidazole drugs undergo reductive activation within the anaerobic environment of the bacterium to form reactive nitroso-free radicals that cause DNA strand breakage and inhibit nucleic acid synthesis (StatPearls, 2023).